ATOS

Atossa Therapeutics Announces Year-End 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, February 28, 2022
GLOBE, Development, Population, PIND, Security (finance), ATOS, Administration, Research, COVID-19, Therapy, Company, Infection, Breast cancer, Safety, U.S. Securities and Exchange Commission, Trial of the century, Woman, API, IND, Part, FDA, R, Nasdaq, Forward-looking statement, Patient, CRO, Form 10-K, Pharmaceutical industry, Birth control, G&A, Endoxifen, Atossa

Key developments from Q4 2021 and to date include:

Key Points: 
  • Key developments from Q4 2021 and to date include:
    Initiated enrollment of our Phase 2 clinical study of proprietary oral Z-endoxifen (or Endoxifen) in Sweden.
  • Completed enrollment of Part A of our Phase 1/2a clinical study of AT-H201 in Australia, consisting of single ascending dose cohorts in healthy participants.
  • Compensation also increased$460due to the addition of a new employee during 2021, increased hourly employees time, andemployee bonusincreases over the prior year.
  • Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious diseases with a current focus on breast cancer and COVID-19.

Rave Mobile Safety Selected to Power California’s Statewide Emergency Mass Notification System

Retrieved on: 
Monday, February 28, 2022
Mobile, Wireless, Technology, Other Technology, Integrated Public Alert and Warning System, Partnership, TCV, Twitter, ATOS, School, University, Tsunami, Organization, Atos, Earthquake, Rave Alert, LLC, IPAWS, GIS, Wildfire, Disaster, LinkedIn, Rave Mobile Safety, Emergency, Rave, Solution, Communication, Nightclub, Risk management, Facebook

Raves highly flexible and configurable system will consolidate and expand current capabilities into one state-wide solution.

Key Points: 
  • Raves highly flexible and configurable system will consolidate and expand current capabilities into one state-wide solution.
  • The solution seamlessly integrates with Californias NG911 system, enabling agencies to ensure phone numbers and GIS data sets are synchronized.
  • Rave Mobile Safety is the leading provider of critical communication and collaboration technology used to save lives, manage crisis incidents and increase resiliency.
  • From major disasters and crisis events to everyday emergencies and operational incidents, the Rave platform enables critical data sharing, mass notification and emergency response coordination.

IoT in Manufacturing Market worth $87.9 billion by 2026 - Exclusive Research by MarketsandMarkets™

Retrieved on: 
Monday, February 21, 2022
Cloud, Knowledge, Workforce, Bosch, SME, Region, Connectivity, SAP, Software AG, Application security, PTC, Growth, Application enablement, Component, Wireless connection management utility, Siemens, ATOS, IBM, Process optimization, Intelligence, GE Automation & Controls, Industry, Organization, IO, Mobile device management, Zebra Technologies, Schneider Electric, Adoption, Cloud computing security, Solution, Software, HCL, Internet, IOT, App Store (iOS/iPadOS), Maintenance, Foghorn, GEM, Endpoint security, Research, Network, Risk management, Video game, Marketing, Vertical, Application, Huawei, Oracle, Intel, Platform, Microsoft

Services play a vital role in the IoT in Manufacturing Market, as they enable manufacturing enterprises to establish digitized and connected manufacturing processes with mass customization and a self-configuring, automated manufacturing floor.

Key Points: 
  • Services play a vital role in the IoT in Manufacturing Market, as they enable manufacturing enterprises to establish digitized and connected manufacturing processes with mass customization and a self-configuring, automated manufacturing floor.
  • The services segment is considered an important component of the IoT in Manufacturing Market, as it majorly focuses on improving the business operations and reducing unnecessary expenses and overheads of the manufacturing enterprises.
  • By Organization size, large enterprises are expected to hold the largest market size Large enterprises hold a larger market size in the present market.
  • North America is expected to hold the largest market size in the global IoT in Manufacturing Market during the forecast period.

IoT in Manufacturing Market worth $87.9 billion by 2026 - Exclusive Research by MarketsandMarkets™

Retrieved on: 
Monday, February 21, 2022
Cloud, Knowledge, Workforce, Bosch, SME, Region, Connectivity, SAP, Software AG, Application security, PTC, Growth, Application enablement, Component, Wireless connection management utility, Siemens, ATOS, IBM, Process optimization, Intelligence, GE Automation & Controls, Industry, Organization, IO, Mobile device management, Zebra Technologies, Schneider Electric, Adoption, Cloud computing security, Solution, Software, HCL, Internet, IOT, App Store (iOS/iPadOS), Maintenance, Foghorn, GEM, Endpoint security, Research, Network, Risk management, Video game, Marketing, Vertical, Application, Huawei, Oracle, Intel, Platform, Microsoft

Services play a vital role in the IoT in Manufacturing Market, as they enable manufacturing enterprises to establish digitized and connected manufacturing processes with mass customization and a self-configuring, automated manufacturing floor.

Key Points: 
  • Services play a vital role in the IoT in Manufacturing Market, as they enable manufacturing enterprises to establish digitized and connected manufacturing processes with mass customization and a self-configuring, automated manufacturing floor.
  • The services segment is considered an important component of the IoT in Manufacturing Market, as it majorly focuses on improving the business operations and reducing unnecessary expenses and overheads of the manufacturing enterprises.
  • By Organization size, large enterprises are expected to hold the largest market size Large enterprises hold a larger market size in the present market.
  • North America is expected to hold the largest market size in the global IoT in Manufacturing Market during the forecast period.

Hardware Security Modules Market size worth $ 7.9 Billion, Globally, by 2028 at 12.4% CAGR: Verified Market Research®

Retrieved on: 
Wednesday, February 16, 2022
Final good, Hewlett Packard Enterprise, Adoption, ATOS, Government, Health, Retail, Market research, Ownership, FIPS 140-2, Infineon Technologies, Technology, Cypress Semiconductor, Geography, Hardware, USD, Organization, IBM, Acquisition, Investment, Financial services, Gaps, HSM, Authentication, CAGR, Cryptocurrency, Cypress, Industry, YubiKey

According to Verified Market Research, the Global Hardware Security Modules Market size was valued at USD 3.1 Billion in 2020 and is projected to reach USD 7.9 Billion by 2028, growing at a CAGR of 12.4% from 2021 to 2028.

Key Points: 
  • According to Verified Market Research, the Global Hardware Security Modules Market size was valued at USD 3.1 Billion in 2020 and is projected to reach USD 7.9 Billion by 2028, growing at a CAGR of 12.4% from 2021 to 2028.
  • The Hardware Security Modules help to safeguard the user's personal information, digital transactions, and sensitive organization's assets against exposure and manipulations.
  • Moreover, the increasing adoption of Hardware Security Modules in various end-use industries like banking and financial services, government, technology, and communications, manufacturing, utility and energy, retail, healthcare, and life sciences drive the market for Hardware Security Modules.
  • Verified Market Research has segmented the Global Hardware Security Modules Market On the basis of Type, Application, Industry, and Geography.

Hardware Security Modules Market size worth $ 7.9 Billion, Globally, by 2028 at 12.4% CAGR: Verified Market Research®

Retrieved on: 
Wednesday, February 16, 2022
Final good, Hewlett Packard Enterprise, Adoption, ATOS, Government, Health, Retail, Market research, Ownership, FIPS 140-2, Infineon Technologies, Technology, Cypress Semiconductor, Geography, Hardware, USD, Organization, IBM, Acquisition, Investment, Financial services, Gaps, HSM, Authentication, CAGR, Mobile phone, Cryptocurrency, Cypress, Industry, YubiKey

JERSEY CITY, N.J., Feb. 16, 2022 /PRNewswire/ -- Verified Market Research recently published a report, "Hardware Security Modules Market" By Type (LAN-Based HSM/Network-Attached HSM, PCI-e-Based/Embedded Plugins HSM, USB-Based/Portable HSM), By Application (Authentication, Database Encryption, PKI Or Credential Management), By Industry (Retail and Consumer Products, Banking and Financial Services, Government), and By Geography. According to Verified Market Research, the Global Hardware Security Modules Market size was valued at USD 3.1 Billion in 2020 and is projected to reach USD 7.9 Billion by 2028, growing at a CAGR of 12.4% from 2021 to 2028.

Key Points: 
  • According to Verified Market Research, the Global Hardware Security Modules Market size was valued at USD 3.1 Billion in 2020 and is projected to reach USD 7.9 Billion by 2028, growing at a CAGR of 12.4% from 2021 to 2028.
  • The Hardware Security Modules help to safeguard the user's personal information, digital transactions, and sensitive organization's assets against exposure and manipulations.
  • Moreover, the increasing adoption of Hardware Security Modules in various end-use industries like banking and financial services, government, technology, and communications, manufacturing, utility and energy, retail, healthcare, and life sciences drive the market for Hardware Security Modules.
  • Verified Market Research has segmented the Global Hardware Security Modules Market On the basis of Type, Application, Industry, and Geography.

Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Recent Accomplishments and Strategy for 2022

Retrieved on: 
Thursday, January 27, 2022
U.S. Securities and Exchange Commission, Inhalation, Trial of the century, American Cancer Society, Forward-looking statement, Female, Security (finance), Breast, Patient, Infection, GLOBE, Acquisition, Biostatistics, Nasdaq, Form 10-K, Woman, Treatment, Breast cancer, Cancer, Emergency, Safety, Karolinska Institute, Degenerative disease, Coronavirus, Department, CRO, Research, PIND, Severe acute respiratory syndrome coronavirus 2, Hospital, Menopause, Disease, API, ATOS, CEO, FDA, COVID, Vaccine, COVID-19, Risk, IND, Incidence, Male, Furin, B cell, Therapy, MBD, Letter, Face, Hydroxychloroquine, Recurrence, Goal, ER, Public health, Epidemiology, Pharmaceutical industry, Medical imaging, Dietary supplement, Management, Atossa, Endoxifen, Delta, Omicron

Despite the launch of highly efficacious vaccines during 2021, the toll that COVID-19 was taking on public health was not reduced.

Key Points: 
  • Despite the launch of highly efficacious vaccines during 2021, the toll that COVID-19 was taking on public health was not reduced.
  • We raised over $110 million in capital in 2021 and we are well positioned to execute on our programs in 2022.
  • She has now received our oral Endoxifen for over three years without recurrence of breast cancer or significant side effects.
  • On behalf of the board of directors, management and employees of Atossa Therapeutics, we thank you for your investment and continued support.

Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201

Retrieved on: 
Tuesday, January 18, 2022
Forward-looking statement, ATOS, Patient, Atossa, Form 10-K, COVID-19, Severe acute respiratory syndrome coronavirus 2, B cell, Safety, Breast cancer, GLOBE, Breast, U.S. Securities and Exchange Commission, Nasdaq, Ethics committee, Infection, Therapy, FDA, Security (finance), Coronavirus, Omicron, Pharmaceutical industry, Part

Part A of the study, which consisted of a single ascending dose group of 4 cohorts of healthy participants, has now been completed.

Key Points: 
  • Part A of the study, which consisted of a single ascending dose group of 4 cohorts of healthy participants, has now been completed.
  • The Australian Human Research Ethics Committee has reviewed the safety data from Part A and has approved the study to proceed to Part B.
  • A record number of hospitalizations driven by the Omicron variant is producing a crisis at many healthcare facilities.
  • The Phase 1/2a placebo-controlled study will enroll a total of 60 healthy participants and moderately-ill hospitalized COVID-19 patients.

Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden

Retrieved on: 
Wednesday, December 22, 2021
U.S. Securities and Exchange Commission, Epidemiology, Nasdaq, Mammography, Tamoxifen, Risk, FDA, Cancer, Infection, MBD, CEO, Form 10-K, Legislation, Forward-looking statement, Man, Health, COVID-19, Karolinska Institute, Incidence, Trial of the century, Department, Breast cancer, Breast, Atossa, ATOS, Therapy, Safety, Security (finance), Biostatistics, Woman, GLOBE, Pharmaceutical industry, Medical imaging, Endoxifen

This study will help determine the relationship between daily doses of Endoxifen and reduction in breast density and will help us further assess safety and tolerability.

Key Points: 
  • This study will help determine the relationship between daily doses of Endoxifen and reduction in breast density and will help us further assess safety and tolerability.
  • The study, known as the Karisma-Endoxifen study, is a Phase 2, randomized, double-blind, placebo-controlled, dose-response study of Atossas proprietary oral Z-Endoxifen in healthy premenopausal women with measurable breast density.
  • The primary objective of the study is to determine the dose-response relationship of daily oral Z-Endoxifen on breast density reduction.
  • Atossa has been developing its proprietary Z-Endoxifen for breast cancer and other breast conditions and has successfully completed three Phase 1 clinical studies (including a study in men) and two Phase 2 clinical studies.

ATOS Healthcare Executive, Narendar Reddy, Named as President and CEO of EZEN (A Digital Health IT Company Based in Princeton, NJ)

Retrieved on: 
Wednesday, December 15, 2021
Reddy, Work, List of life sciences, Industry, Atos Syntel, Providers, Medical device, ATOS, Risk, CEO, Data, Leadership, Analytics, GLOBE, Digital technology, Digital, Management, Pharma, Health care

EZEN announced, today, the appointment of Narendar Reddy as its second Chief Executive Officer in the company's 21-year history.

Key Points: 
  • EZEN announced, today, the appointment of Narendar Reddy as its second Chief Executive Officer in the company's 21-year history.
  • Reddy, who will also serve as president, will take charge on Jan.3, 2022 - succeedingco-founder and longtime CEO - Kumar.
  • Kumar will continue to be the board member and will look after finance and strategy for the company.
  • EZEN is a 21-year-old, US-based, US-owned, digital technology company focused on healthcare industry (Providers, Medical Devices, and Pharma) delivering Data, Digital, Analytics and compliance services.